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Abstract
Cytogenomic microarray testing allows the detection of submicroscopic genomic rear-
rangements, commonly denominated copy number variations (CNVs) that are implicated 
with many neurodevelopmental disorders, dysmorphic features, multiple congenital 
anomalies, hematological and solid tumors, and complex disorders and traits in both 
humans and animals. On the other hand, this approach is also widely used for the iden-
tification of structural variations that are applied as a biomarker in pharmacogenomics, 
agriculture, and animal selection and breeding. The chromosomal microarray analysis 
(CMA) has been applied for over a decade to screen for submicroscopic genomic gains 
and losses in DNA sample in both diagnostic and functional scenarios. Herein, we pres-
ent an overview of the fundamental concepts of cytogenomics and its potential applica-
tion in human genetic diagnosis, agrigenomics, mutagenesis, and pharmacogenomics.
Keywords: microarray analysis, SNP array, CNV, array CGH
1. Introduction
Since the use of high-resolution chromosome banding and molecular cytogenetic methodolo-
gies, several chromosomal aberrations have been identified. Despite genome-wide detection 
capacity of these technologies, the rearrangements still remain visibly undetectable, which 
can be explained by microscopic resolution limitations and the lack of knowledge regarding 
the regions under investigation.
In the 1990s, the array chromosome-based comparative genomic hybridization (array CGH) 
was established and began to be used for the detection of significant submicroscopic losses 
and gains with high sensitivity. It was initially applied to analyze copy number changes in 
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tumors, and it was able to detect changes as small as 50 kb in size, with a resolution up to 1000 
times higher than the karyotype. Subsequently, the array CGH methodology was optimized 
and applied to detect unbalanced constitutional rearrangements [1–4]. Initially, bacterial arti-
ficial chromosomes (BACs) and fosmid clones were used in array CGH. However, it became 
clear that not only larger DNA insert constructed in BAC vector but also PCR products and 
oligonucleotide sequences were good targets for array CGH [5–7]. Microarray approaches 
offer a high resolution and relatively quick way for genome-wide analysis, increasing the 
potential possibilities of genomic scrutiny in clinical scenario as well as its potential appli-
cation in many other distinct structural genome investigations. In addition, chromosomal 
microarray analysis (CMA) is useful to estimate the breakpoints of the DNA sequences that 
can reveal potential mechanisms and risk factors underlying the occurrence of chromosome 
rearrangement, especially in the case of recurrent rearrangements [8]. Nowadays, chromo-
somal microarray analysis (CMA) is used as a powerful tool to reveal copy number variants 
thought to play an important role in the pathogenesis of a variety of disorders or the develop-
ment of complex traits. Thus, genomic variants can be used as a biological biomarker.
Herein, we present an overview of the fundamental concepts of cytogenomics and the poten-
tial application of this technology in human genetic diagnosis, agrigenomics, mutagenesis, 
and pharmacogenomics.
2. Fundamental concepts of cytogenomics: understanding the tool  
of arrays
Cytogenomic analysis comprises the use of microarray-based technologies for the investiga-
tion of specific loci and the entire genome [9]. It has been used for the detection of copy num-
ber variation (CNV), defined as genomic intervals that deviate from the normal diploid state 
that can vary in size ranging from a few base pairs to mega base pairs [10]. The microarray 
technologies are frequently nominated as chromosomal microarray analysis (CMA), known 
as comparative genomic hybridization (CGH) and SNP array (Figure 1). CMA could be used 
for a dual role in SNP (single nucleotide polymorphism) and CNV-based association studies 
and in humans for the evaluation of patients with various diseases and congenital malforma-
tions [11, 12].
Initially, the CMA was based on the same principles of chromosome-based comparative 
genomic hybridization. The CGH was developed in the early 1990s to screen for unbalanced 
rearrangements in whole genomes [3]. The CGH consists in the simultaneous hybridiza-
tion of labeled test DNA and normal reference DNA onto normal metaphase chromosomes 
spread on glass slides. Metaphase CGH was widely used to identify chromosomal numerical 
alterations associated with solid tumors [13, 14]. Overall, the resolution of metaphase CGH 
is the same of G-banding cytogenetics, limited to 5–15 Mb. Moreover, experiments require 
cytogenetic expertise for the preparation of suitable metaphase chromosomes [3]. Due to its 
resolution limitations, the metaphase CGH became restricted to cancer research and did not 
demonstrate feasibility for analysis of genomic rearrangements in patients with developmen-
tal disorders. Subsequently, CGH was implemented as microarrays replacing the metaphases 
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CGH by cloned DNA segments as genomic reference to be used as targets for the hybridiza-
tion, improving the potential for the detection of small chromosomal imbalances and increas-
ing its resolution in more than tenfold [14].
Figure 1. Fundamental concepts of chromosomal microarrays. Currently, the most widely used arrays are comparative 
genome hybridization arrays (aCGH) and single-nucleotide polymorphism arrays (aSNP). Both microarray-based 
technologies are able to detect genomic imbalances based on the spectral differences of the fluorescent dyes used to label 
test and reference DNA in aCGH and test DNA in aSNP. Sample analyses are possible with the aid of computational 
tools designed to call, view, summarize, and report chromosomal aberrations, including copy number gain or loss, 
across the genome. *CN: Copy Number.
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The pieces of information regard the DNA sequence of the human genome, which was 
obtained by the Human Genome Project, making it possible for the construction and char-
acterization of DNA libraries that could be cloned using bacterial artificial chromosomes 
(BACs) and fosmids as vectors [15, 16]. The array CGH was introduced having known 
clinically relevant microdeletion genomic DNA segments in BAC clones [10]. However, 
the relatively large size of the initial clones (170 kb for BACs and 40 kb for fosmids) lim-
ited the resolution of the arrays which is dependent on the distances between probes, the 
length of the clones, and how both probes and clones are distributed across the genome 
[14, 17]. With the emerging of new protocols, different probes, including small insert clones 
(1.5–2.5 kb), cDNA clones (0.5–2 kb), PCR products (0.1–1.5 kb), and oligonucleotides (25–85 bp), 
have been used in the arrays. However, the oligonucleotides have been more appropriated 
targets for array CGH [5–7, 18]. The oligonucleotide array offers higher resolution and is bet-
ter than BAC in measuring size of CNVs, increasing the detection of small CNVs. Most CGH 
arrays available are designed with oligonucleotides ranging from 50 to 70 base pairs (bp) on 
the probe [19].
According to the International System for Human Cytogenetic Nomenclature [20], in contrast 
to array CGH, in which DNAs from patient and control are labeled with different dyes and 
hybridized to a single slide for array CGH and the alterations in the ratio of the two fluores-
cent dyes indicate a different quantity of DNA in the test sample as compared with the control 
corresponding locations of CNVs, in the SNP arrays, only the patient’s DNA is hybridized to 
the microarray and compared by computer analysis to a pool of genomic DNA from reference 
healthy individuals. Additionally, in SNP arrays, the size of the oligonucleotides is about 20 
bp and was designed initially to detect genotypes for thousands to hundreds of thousands of 
SNPs across the entire genome with the focus on genome-wide association studies [19, 21]. 
SNP arrays can also enable the detection of CNVs, but opposed to array CGH, each probe is 
located at an SNP and can determine the genotype of the corresponding SNP, and the current 
SNP arrays with median inter-SNP distances of <0.7 kb ensure the high density of genome 
coverage [22, 23]. There are many commercial platforms for microarray analysis. Array CGH 
allows the detection of non-polymorphic region and has been manufactured by Agilent 
Technologies (Santa Clara, CA) and NimbleGen (Roche Nimble-Gen Inc., Madison, WI), and 
more recently, Agilent Technologies is offering array CGH with inclusion of SNP markers. 
The SNP arrays, manufactured by Illumina (San Diego, CA) and by Affymetrix (Santa Clara, 
CA), have markers for the detection of polymorphic and non-polymorphic regions.
Besides the detection of CNVs, SNP arrays have some advantages in relation to array CGH. The 
SNP markers can also detect long contiguous stretches of homozygosity (LCSH), low-level 
mosaic aneuploidies, and chimerism. The detection of LCSH could indicate uniparental isodi-
somies (UPD) and consanguinity. LCSH distributed in several regions of chromosomes is 
characterized by genetic identical by descent; on the other hand, when LCSH was identified 
in a single chromosome, this observation may indicate UPD [24]. The major disadvantage of 
SNP array and array CGH is the inability to detect balanced chromosome rearrangements 
because balanced rearrangements show no copy number alterations. Thus, array method-
ologies do not replace G-banding karyotype for the detection of balanced structural rear-
rangements. However, they detect abnormalities that are cytogenetically cryptic by G-banded 
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chromosome analysis. It is important to remember that CMA testing cannot detect balanced 
karyotypic rearrangements such as reciprocal translocations that could be clinically significant 
if they disrupt a critical gene. For clinical indications with increased risk for a balanced chro-
mosome rearrangement, such as recurrent pregnancy loss, G-banding chromosome analysis 
should remain a primary diagnostic test [23]. Additionally, in agrigenomics, SNP arrays have 
facilitated marker-assisted selections, genome-wide association studies, quantitative trait loci 
analyses, parentage, and traceability, helping in genomic selection programs.
The primary focus for microarrays has been biomedical-related analyses. However, applica-
tions for array technology have broadened to include such fields as plant and animal genotyp-
ing and pharmacogenomics. The number of CNVs identified has increased as a function of the 
increased resolution used by the array technologies. The wide use of arrays has allowed their 
application in agrigenomics providing a powerful and flexible range of genotyping calls use-
ful for genomic selection programs for plants and animals, helping researches and breeders to 
develop healthier and more productive crops and livestock [25, 26]. Besides, array technolo-
gies can be used in pharmacogenomic research for the investigation of potential associations 
between genomic variation and individual drug response. Several SNP-based microarrays 
are intended to provide information about specific polymorphisms associated with variable 
drug responses within individuals in a population, which could increase treatment’s overall 
efficacy and decrease the incidence of adverse events [27, 28]. Moreover, the extensively use 
of CMA has not only contributed to the identification of CNVs and SNP related to human 
variability but also contributed to the identification of rearrangements implicated in a variety 
of diseases such as lifestyle diseases, cancer, autoimmune diseases, and neurodevelopmental 
disorders, including intellectual disability, autism spectrum disorder, global developmental 
delay, and neuropsychiatric disorders such as schizophrenia, creating a new field of investi-
gation which has transformed the clinical practice [16, 24, 29].
2.1. Application in the diagnosis of human diseases
Genomic gains and losses, defined as CNVs, often cause a wide variety of specific and complex 
phenotypes, resulting from alterations in the normal dosage of genes, which cause multiple 
malformation syndromes, neurodevelopmental disorders (NDD), multiple congenital anom-
alies (MCA), and dysmorphic features. Nowadays, the improved resolution of the microarray 
technologies has allowed the identification of cryptic chromosomal alterations, increasing 
the knowledge of the etiology of genomic disorders and offering potential advantages in the 
patient’s follow-up and management [3, 30].
Since 2010, CMA is widely recognized and recommended as the first-tier cytogenomic diag-
nostic test for individuals with unexplained developmental delay/intellectual disability (DD/
ID), autism spectrum disorders (ASDs), or multiple congenital anomalies, increasing the diag-
nostic yield around 10–25% [16, 30–32]. DD and ID are defined as several significant delays 
in developmental areas, including cognitive, speech, social/personal, fine/gross motor, and 
daily activities. DD is described for children less than 5 years old, and ID is diagnosed at 
or after the age of 5 years old, with the intelligence quotient less than 70. ASD is a complex 
spectrum of neurodevelopmental disorders, including autism, Asperger syndrome, pervasive 
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developmental disorder, and childhood disintegrative disorder. MCAs are defined as mul-
tiple major structural malformations that cannot be explained by an underlying syndrome 
or sequence. These disorders might have a genetic etiology involving the gains and losses of 
CNVs and loss of heterozygosity (LOH), and the clinical consequences of these rearrangements 
are commonly associated with location, size, and the gene content (Figures 2 and 3) [32–34].
In a study with children with ID/DD, ASD, and/or MCAs from Hong Kong, the application 
of array CGH demonstrated a diagnostic yield of 11% for pathogenic and likely pathogenic 
CNVs [35]. Another study with a cohort of 339 patients with neurodevelopmental disorders 
and/or multiple congenital anomalies using the array CGH identified a detection rate of 
pathogenic CNVs of 20.6% [30]. Combining both array CGH and SNP array in a single plat-
form, it is possible to make the most effective clinical diagnostic offering simultaneously 
Figure 2. SNP array revealed a copy number loss of chromosome band 17q21.31 of approximately 0.56 Mb in size 
(arr[hg19] 17q21.31(43.703.801–44.212.416) × 1). This region involves 10 OMIM genes (LOC644172, CRHR1, MGC57346, 
C17orf69, MAPT-AS1, SPPL2C, MAPT, MAPT-IT1, STH, and KANSL1) related to Koolen-De Vries Syndrome 
(MIM610443). The red bar indicates the deleted region and the green bars indicated morbid genes.
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identification of CNVs and LOH, as reported by different researches. A comparative study 
between high-resolution SNP arrays and CGH microarrays revealed that the use of SNP 
arrays increased the diagnostic yield in children with ID/MCA because these platforms 
permitted the identification of LOH, which can unravel recessive disorders [36]. Using the 
combining SNPs with customized exon-targeted oligonucleotide array in a cohort of 3240 
patients, Wiszniewska et al. [24] provided a comprehensive approach for the identification 
of clinically relevant copy number neutral changes in addition to CNVs in a single assay. 
A study using CMA for 42 Korean patients with unexplained DD, ID, ASD, and MCA 
identified clinically relevant CNVs in 66.6% of patients [33]. Therefore, microarray-based 
Figure 3. SNP array revealed a gain in copy number of chromosome band 22q11.1, spanning 1.75 Mb (arr[GRCh37] 
22q11.1q11.21(16.888.899–18.644.773)×4). This gain as indicated in blue bars and comprise 12 OMIM genes (XKR3, 
IL17RA, CECR1, CECR), SLC25A18, ATP6V1E1, BID, MICAL3, MIR648, PEX26, TUBA8, and USP18), indicated with gray 
and green bars, related with Chromosome 22q11.2 Duplication Syndrome (OMIM608363).
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technologies have become a powerful tool for the identification of genomic rearrange-
ments smaller than 5 Mb that are associated with neurodevelopmental disorders.
In addition to the usefulness of CMA to help increase the diagnostic rate for ID, DD, ASDs, 
and MCA, a variety of human conditions, such as epilepsy, schizophrenia, bipolar disorder, 
and attention deficit hyperactivity disorder, have been reported in some individuals whose 
CNVs have an important causative role [23, 37–42]. Besides the roll of CNVs in the devel-
opment of neurodevelopmental disorders, CNVs might also contribute to genetic variation 
in stature in a general population. This conclusion was driven from the observation that in 
children with short stature lower-frequency copy number variants play a role in the genetic 
basis of height [43]. Additionally, studies of CNVs in idiopathic short stature (ISS) individuals 
demonstrated that CMA is a promising approach for the identification of pathogenic CNVs in 
patients with ISS and could contribute for the recognition of candidate genes associated with 
growth pathways in humans [44, 45].
CMA testing, especially using SNP-based array, has improved the understanding of genetic 
causes of many types of human disease and added new pieces of information about gains 
and losses in the genome in a large variety of hematological malignancies and solid tumors. 
Additionally, loss of heterozygosity, which is frequently implicated in the tumorigenesis of 
a variety of cancers, could be detected using SNP array. So, CMA has played an important 
role to help in diagnosis, prognosis, risk stratification, and therapy for cancer patients [46, 47].
CMA has become a widespread strategy of genetic diagnosis in postnatal settings, especially 
evaluating children with neurodevelopmental disorders and multiple congenital malforma-
tions [48]. Moreover, the implementation of CMA in prenatal settings has helped physicians 
to identifying chromosomal abnormalities in fetuses harboring anatomical anomalies in the 
ultrasound, influencing on healthcare delivery in many countries [49]. CMA achieves nearly 
100% accuracy rates when applied to identify common aneuploidies in prenatal specimens 
compared to G-banding karyotyping. Overall, studies showed that in pregnancies with 
fetal structural anomalies and karyotype with no numerical or structural alterations CMA 
increased the diagnostic yield around 7%. On the other hand, for all other indications, the 
increment in the diagnostic yield by CMA has remained around 2% [50, 51]. Taking into con-
sideration the aforementioned information, in 2016 the American Congress of Obstetricians 
and Gynecologists (ACOG) recommended CMA as the first-tier test for the diagnostic evalu-
ation of fetal structural anomalies. However, the challenge of CMA in prenatal settings is 
the adequate classification of CNVs as pathogenic and variants of unknown significance 
(VOUS) [50, 52]. To minimize the reporting of uncertain findings, the practice guideline from 
Canada issued by the Society of Obstetricians and Gynecologists of Canada (SOGC) and the 
Canadian College of Medical Geneticists (CCMG) recommended not to report VOUS smaller 
than 500 kb or VOUS smaller than 1 Mb for losses and gains, respectively [52].
For the diagnosis of human diseases, the microarray platforms should use probes derived 
from closely spaced genomic loci and have probes concentrated in clinically relevant genes 
and genomic loci, allowing the detection of smaller CNVs within disease-associated regions. 
The identification of pathogenic or likely pathogenic CNV by CMA offers benefits for the 
patient and family, bringing information about prognosis, allowing for appropriate genetic 
counseling, and adequate patient’s management and follow-up for future disclosures [23].
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2.2. Application in agrigenomics
2.2.1. Livestock microarray analysis
SNP-based genotyping technologies have become the first-tier methodology in programs of 
animal and plant breeding for genomic selection [53]. In this context, the use of SNP arrays 
in organisms of economic interest has facilitated the association between a given SNP with 
desired productive phenotypes, promoting a positive impact in the economy and contribut-
ing to consolidate the technology as a powerful tool to select animals and plants with higher 
genomic value [54].
The animal genomic is a reality in breeding programs, and the application’s impact of these 
methodologies can be noticed in several areas of animal production [55]. The commercial use 
of genomic markers is driven based on the need to develop efficient selection and production 
systems. For instance, selection assisted by genomic markers has been applied to swine breed-
ing aiming for little size and higher meat quality. On the other hand, in bovine, animal selec-
tion is used for meat tenderness and higher milk production. Still, for sheep, animal selection 
is used to increase reproductive efficiency and muscle deposition [56].
Although microarray analysis may reflect a promising future in the agricultural setting to 
economically produce labor and commodities, the efficiency of microarrays and other innova-
tive methodologies applied to livestock production will always be affected by situations of 
difficult control, including measurements of traits, phenotypic variance, and low heritabil-
ity [57]. Inadequate phenotyping could negatively affect, limit, and hinder the usefulness of 
genetic information in breeding strategies. Improvements and the use of SNP array, followed 
by cost reduction for genotyping and genome sequencing by Sanger or NGS, have created 
the possibility to use genomic information for the creation of livestock and supported the 
emergence of genomic selection programs [58].
The development and application of genomic selection in livestock breeding programs have 
benefited from the consolidated knowledge generated by classical breeding programs, in 
particular, information derived from mapping of the Quantitative Trait Loci (QTLs). QTL is 
characterized as a region of the genome responsible for the expression of a phenotypic trait, 
which has a continue distribution [25]. This observation is supported by the fact that the main 
phenotypic characteristics targeted by genomic and genetic breeding programs are polygenic 
and controlled by several loci, each one adding to the final effect observed in the phenotype. 
In the aforementioned scenario, genomic selection must be conceived as a process of making 
decisions regarding the selection of the best-fit animals based on their estimated genomic val-
ues. Genomic estimated breeding values (GEBVs) are most commonly obtained by Bayesian 
models, and it is nowadays considered to be an important step for the success of genomic 
selection [59]. In summary, GEBVs are the result of the presence of meaningful genetic mark-
ers, identified through a dense array of SNPs equally spaced throughout the whole genome, 
contained within all known QTLs from previously studied livestock [60].
There are different SNP arrays available for livestock genomic analysis. Schaefer et al. [61] 
designed two different genotyping platforms and demonstrated the application of custom-
ized SNP array for domestic horse. Júnior et al. [62] observed the importance of identification 
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of genomic region associated with puberty and early pregnancy to females of Zebu cattle. 
Gutierrez et al. [63] used a high-density ovine chip (700 K) to search signatures of selection 
related to dairy production in sheep and demonstrated the usefulness of the array in the 
identification of regions of economic interest in dairy sheep. The application of SNP array 
for genomic selection has been useful to determine genetic attributes and contributed for the 
genomic selection of traits of economic interest.
The SNP arrays available to estimate genomic values in farm animals can be divided into 
two categories, according to the time of their development and use. First, there were the 
SNP arrays from 2000 to 2012, characterized by the development of arrays based on the 
sequence of reference genomes of farm animals. Most of the arrays were developed by mul-
tinational companies, including genome Illumina, Affymetrix, ARK Genomics, and Applied 
Biotechnologies. Secondly, the arrays used from 2012 on are based on the genome of selected 
animals, including the possibility of customizing the array for a given property.
In general, the positive aspects for using commercially available SNP arrays are as follows: (a) 
genetic polymorphism can be estimated in different breeds, including synthetic cross breeds, 
and (b) the SNPP panels are able to discriminate genomic variability even in animals with 
close genetic makeup, especially considering the elevated level of inbreeding, for instance, 
in pigs and poultry lineages. With respect to the negative aspect of using SNP arrays, the 
following are noteworthy: (a) high cost per genotyped animal, (b) unavailability of personnel 
and laboratories qualified to generate and analyze genomic data, and (c) in the same array 
makers for different QTLs and different aptitudes reduction of the availability of genomic 
data for the trait of interest. Carroll and Charo [55] called the attention upon an array for 
bovine selection. The markers in that array were chosen to select meat and milk production. 
The total of informative SNPs was reduced based on the total number of SNPs in the array. 
Goddard [64] reported that perhaps the two most critical issues that hinder the usefulness of 
genomic selection in the agribusiness industry are the lack of qualified personnel and the cost 
per animal for their genotyping.
Lately, the potential of array customization and the advancement of genome sequencing 
methodologies have boosted the applicability of genotyping farm animals and reduced the 
cost per animal. Moreover, NGS is a powerful tool to generate information on the whole 
genome of selected animals together with adequate animal phenotyping, which will contrib-
ute to adequately estimate true genomic breeding values for the livestock. Several authors 
have pointed out that the advancement of genome-wide association studies (GWAS) has pro-
viding excellent and efficient information to be used in livestock genomic selection programs 
(GSP) [54, 57, 65]. GWAS has allowed the identification of candidate genes potentially associ-
ated with phenotypes of economic interest (Figure 4). Thus, the piece of information gener-
ated for a given herd has become more powerful to predict its genomic merit and also to be 
used to assist adequate selection of the desired animal phenotype. Thereby, genomic breeding 
values have become even more useful and accurate, contributing to efficient decision-making 
by herd managers and producers.
Bosch et al. [67] have addressed the final cost for poultry genotyping considering two distinct 
arrays from the same company, namely, ChickenSNP50 and ChickenSNP600K, representing 
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both the early and the state-of-the-art arrays, respectively. The author reported that the geno-
typing challenge has remained the cost per animal, which has a negative impact on genomic 
selection. At first, genotyping as a whole has become cheaper. Nevertheless, the cost per ani-
mal has not reduced satisfactory. Manufactures claim that the new arrays will collect more 
significant SNPs to be used in breeding strategies (Figure 5), justifying the increase in the cost 
per animal. Similar arguments have been displayed by different authors [65, 67, 68] who also 
claim a steadfast increase in the use of high-density SNP arrays from both academic research-
ers and commercial facilities to assist with livestock breeding and genomic selection globally.
Much debate around the SNP arrays customarily is used for bovine genotyping, especially 
for selection of meat and dairy animals. Specialists have claimed that low-density arrays has 
a reduced capacity to predict the phenotype in Bos taurus indicus mostly because the markers 
in the array are more representative of Bos taurus Taurus, affecting mainly the minor allele 
Figure 4. Manhattan plotting showing the distribution of the significant values of SNPs per bovine autosomal 
chromosomes with respect to 305-day milk yield in Girolando. The GWAS disclosed 7 SNPs associated with milk 
production trait in dairy cattle with a p value <10−5 and a false discovery rate of 6.5% according to the study of milk 
production in Girolando [66].
Figure 5. The resolution of the arrays. Illustration indicating the resolution of an array is based on the number of markers 
available to powerfully predict the breed genomic merit related to the desired economical trait.
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frequency (MAF) of several SNPs for some breeds, rendering them non-useful for breed-
ing selection [69]. Hickey [70], Auvray et al. [71], and Mrode et al. [68] have addressed the 
issue of development of future SNP arrays to be applied for bovine selection. They claim that 
new arrays must include a larger number of markers representative of distinct breeds and/
or future arrays must be customized for a specific breed, having less markers, but all chosen 
based on their MAF. At last, it is also noteworthy to mention that array could be replaced by 
WGS, pending only on the cost per animal, a challenge that will be met by the manufacturers. 
Teng and Xiao [72], Bruford et al. [65], and Steyaert et al. [73] considered that as soon as WGS 
becomes economically competitive it will be accessible to promote a new revolution in the 
field of livestock genomic selection and breeding.
2.3. Application in research: from mutagenesis to pharmacogenomics
Microarray methodologies have been impacted in different fields of biological science, allow-
ing the identification of genomic alterations applied in the area of mutagenesis, including 
toxicology, genetic toxicology, as well as pharmacogenomics [74, 75].
In the area of toxicology, gene expression profiles based on microarray analysis can help 
understand the multiple pathways and mechanisms on the action of toxic substances at the 
same time. Furthermore, microarray analyses are important to understand the effects of 
xenobiotics across the genome and the rapid identification of toxic risks of new drugs and 
chemicals. Thus, global analysis of gene expression has the importance of providing a more 
comprehensive view of toxicity than was previously possible, since toxicity usually involves 
changes not only in one or a few genes but is a cascade of gene interactions [74].
Understanding the function of genes is a major challenge in the post genomic era and in order 
to assign the role of genes in molecular networks, strategies such as proteomics, metabolo-
mics, and transcriptomics have been implemented [76]. The gene expression profile of a cell 
determines its function, phenotype, and response to the environment. Thus, the analysis of 
gene expression becomes necessary for the in-depth study of biochemical pathways, regu-
latory mechanisms, and broader cellular function [77]. Some conventional analyses for the 
gene expression profile are optimized only for single-gene investigation. Microarrays have 
been developed as high-performance, efficient, and comprehensive tools for the simultaneous 
study of multiple genes [78]. Therefore, microarray methodologies are being used to study 
the transcriptional profile, leading to the research of new genes and molecular markers, hav-
ing applicability in the field of pharmacogenomics for tracing changes in the expression of 
genes that are sensitive or resistant to a given drug; thus, it can be used to analyze differential 
profiles of gene expression that are induced or repressed by xenobiotics [79, 80].
Pharmacogenomic studies of genes and gene products (proteins) are essential for pharmaco-
logical or toxicological responses to pharmaceutical agents. In addition, it analyzes genetic 
determinants of enzymes, receptors, transporters, and targets that metabolize drugs and that 
influence drug efficacy, safety, and drug-related phenotypes [79]. A current focus of phar-
macogenomic research explores the effect of interindividual genetic differences related to 
drug response by providing information that can be used to inform the appropriate selec-
tion of individual drugs or dosing regimens [27, 79, 81]. Pharmacogenomic research involves 
scanning the entire genome to find single nucleotide polymorphisms (SNPs) that may be 
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associated with drug responses [79]. Genetic polymorphism studies are performed to classify 
individuals according to their drug metabolism or disease response capabilities [81].
In a pilot study, Liljedahl et al. [82] developed a microarray genotyping system for multiplex 
analysis of a panel of SNPs in genes encoding proteins involved in the regulation of blood 
pressure, demonstrating their viability in response to hypertensive drugs. Therefore, micro-
array-based tests have provided a useful tool for simultaneous measurement of relative levels 
of expression of a large number of clinically relevant genes in the context of disease or drug 
responses [83]. Moreover, the application of the technique in the field of pharmacogenom-
ics characterizes and validates new therapeutic targets, their mechanism of action, metabolic 
pathways, undesirable side effects, sensitivity, and toxicity to certain drugs [84].
To date, there is a scarcity of studies on the induction of germ line mutations in humans. 
However, SNP-based arrays can also be applied to monitor individuals exposed to ionizing 
radiation, and it has been proven to be a useful strategy to evaluate potential health risks related 
to environmental mutagens. Costa et al. [85] presented results of the analysis of the effect of 
accidental exposure to low doses of ionizing radiation on the formation of de novo, nonrecur-
rent CNVs in the progeny of a human population accidentally exposed to cesium-137 during 
the radiological accident in Goiânia, Brazil. The high-density SNP array used in that study 
allowed the observation of de novo mutations induced in the germ line of parents exposed to 
very low doses of ionizing radiation. Although the study of Costa et al. [85] is the pioneer in 
the field and requires validation, it shed light on the potential of SNP arrays to unravel CVS to 
be used as useful germ line biomarkers to characterize the exposure of biological systems to 
mutagenic agents. Thus, a new era of possibilities of using CMA to resolve a variety of biologi-
cal questions is upon us and once again the future keep on looking promising.
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